Sinocare Inc
SZSE:300298

Watchlist Manager
Sinocare Inc Logo
Sinocare Inc
SZSE:300298
Watchlist
Price: 25.82 CNY -1.22%
Market Cap: 14.6B CNY
Have any thoughts about
Sinocare Inc?
Write Note

Net Margin
Sinocare Inc

5.3%
Current
8%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
5.3%
=
Net Income
221.7m
/
Revenue
4.2B

Net Margin Across Competitors

Country CN
Market Cap 14.3B CNY
Net Margin
5%
Country US
Market Cap 199B USD
Net Margin
14%
Country US
Market Cap 191.3B USD
Net Margin
29%
Country US
Market Cap 141.3B USD
Net Margin
16%
Country US
Market Cap 134.2B USD
Net Margin
11%
Country IE
Market Cap 104.6B USD
Net Margin
13%
Country US
Market Cap 65.6B USD
Net Margin
9%
Country DE
Market Cap 58.1B EUR
Net Margin
8%
Country US
Market Cap 44.5B USD
Net Margin
74%
Country CN
Market Cap 310B CNY
Net Margin
33%
Country US
Market Cap 36.3B USD
Net Margin
9%
No Stocks Found

Sinocare Inc
Glance View

Market Cap
14.3B CNY
Industry
Health Care

Nestled in the heart of China's burgeoning biotech industry, Sinocare Inc. has steadily transformed itself into a powerhouse in the realm of glucose monitoring and diabetes management. Founded in 2002, the company was driven by an urgent need to address the growing epidemic of diabetes in China and beyond. As diabetes continued to exact a heavy toll both economically and medically, Sinocare sought to leverage advanced technological innovations to pioneer user-friendly and affordable monitoring solutions. By placing a firm emphasis on research and development, the company sharpened its expertise in biosensing technology, allowing it to produce a comprehensive range of glucose monitors, test strips, and related healthcare products that cater not just to hospitals but also empower individuals with diabetes to manage their conditions effectively. In its journey, Sinocare smartly diversified beyond simple diagnostics into broader health management solutions. With an eye on increasing the accessibility and functionality of their products, they pursued strategic alliances and acquisitions, notably acquiring Nipro diagnostic business (now Trividia Health) and PTS Diagnostics. These moves helped broaden Sinocare’s horizons to international markets, offering it a stronger footing in the lucrative U.S. and European markets in addition to its dominant Asian presence. Sinocare makes money through the sale of its monitoring devices and the recurring revenue stream generated by test strips and other consumables. Their integrated approach, combining product sales with digital health management services, helps in building a robust ecosystem around its core offerings. This innovative business model not only boosts their bottom line but positions Sinocare as a critical player in the global fight against diabetes, continuously driving towards a future where chronic disease management is much more convenient and effective.

Intrinsic Value
35.83 CNY
Undervaluation 28%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
5.3%
=
Net Income
221.7m
/
Revenue
4.2B
What is the Net Margin of Sinocare Inc?

Based on Sinocare Inc's most recent financial statements, the company has Net Margin of 5.3%.